Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
KP
Karyopharm Therapeutics Inc.
KPTI
Mkt Cap
$8.8M
Volume
2.62M
Next Earnings
November 2nd
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
KP
KPTI
KP
Karyopharm Therapeutics Inc.
KPTI
News
·
Advanced Endometrial Cancer Clinical Trial Pipeline Analysis: 25+ Key Companies Shaping the Future of Advanced Endometrial Cancer Therapeutics Space | DelveInsight
Mkt Cap
$8.0M
Volume
2.62M
Next Earnings
November 2nd
Chart
Financials
Earnings
News
About
Insider
Filings
Advanced Endometrial Cancer Clinical Trial Pipeline Analysis: 25+ Key Companies Shaping the Future of Advanced Endometrial Cancer Therapeutics Space | DelveInsight
DelveInsight released a comprehensive analysis of the advanced endometrial cancer clinical trial pipeline, identifying 25+ active pharmaceutical companies developing 26+ pipeline drugs. The report highlights emerging therapies including immunotherapies, targeted agents, and antibody-drug conjugates (ADCs) from major players like Pfizer, Genmab, and Incyte Corporation. Recent developments include FDA Fast Track designation for Faeth Therapeutics' PIKTOR combination therapy and positive Phase III results for Merck's sacituzumab tirumotecan, indicating significant momentum in reshaping the advanced endometrial cancer treatment landscape.
GlobeNewswire Inc. · Sep 3, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
Pomerantz LLP is investigating potential securities fraud claims against Karyopharm Therapeutics following the company's disclosure of a retention program offering executives cash awards ranging from $625,000 to $1,725,000. The announcement triggered a significant stock price decline of 21.45% on July 20, 2026, closing at $7.47 per share.
GlobeNewswire Inc. · Aug 4, 2026
Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress
Menarini Group and Stemline Therapeutics announced positive Phase 3 SENTRY trial results showing that selinexor combined with ruxolitinib met the primary endpoint for spleen volume reduction (SVR35) at 49.8% versus 28% for ruxolitinib alone in myelofibrosis patients. The combination also demonstrated a promising early overall survival signal with greater than 50% reduction in death risk, though it did not meet the secondary symptom score endpoint. The safety profile was manageable with no new safety signals observed.
GlobeNewswire Inc. · Jun 14, 2026
International Myeloma Foundation (IMF) Celebrates Myeloma Milestones for 2025 Myeloma Action Month
Myeloma Action Month is an annual global awareness campaign that takes place every March to raise awareness and inspire action for multiple myeloma, a blood cancer affecting over 176,404 people worldwide. This year, the International Myeloma Foundation invites individuals to share their most meaningful myeloma milestones, celebrating resilience, strengthening connections, and inspiring hope.
GlobeNewswire Inc. · Mar 1, 2025
Glioblastoma Multiforme Treatment Market Size to Reach USD 5.68 Bn by 2033
The global glioblastoma multiforme treatment market is expected to grow from $2.78 billion in 2024 to $5.68 billion by 2033, driven by advancements in immunotherapy and research for better treatment options.
GlobeNewswire Inc. · Nov 25, 2024
Down -12.14% in 4 Weeks, Here's Why Karyopharm Therapeutics Looks Ripe for a Turnaround
Karyopharm Therapeutics (KPTI) has been beaten down lately, but the stock is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier, indicating a potential turnaround.
Benzinga · Sep 5, 2024
Advanced Melanoma Clinical Trial Pipeline Analysis - GlobeNewswire
The advanced melanoma therapeutics market is poised for significant growth, driven by the development of innovative biologics, particularly immunotherapy medications. The pipeline report highlights 55+ active players working on 60+ pipeline therapies for advanced melanoma treatment.
GlobeNewswire Inc. · Jul 8, 2024
Karyopharm Therapeutics (KPTI) Q1 2024 Earnings Call Transcript
KPTI earnings call for the period ending March 31, 2024.
The Motley Fool · May 8, 2024
Karyopharm Therapeutics (KPTI) Q4 2023 Earnings Call Transcript
KPTI earnings call for the period ending December 31, 2023.
The Motley Fool · Feb 29, 2024
Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -24.14% and 0.74%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Research · Feb 29, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
KP
KPTI
Karyopharm Therapeutics Inc.
Buy
Sell
Market
Limit
Soon
KPTI
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any KPTI yet.
Related Tickers
Earnings